# CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

> **NCT01029366** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 26 (actual)

## Conditions studied

- Hematopoietic/Lymphoid Cancer
- Adult Acute Lymphoblastic Leukemia in Remission
- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Prolymphocytic Leukemia
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Adult Diffuse Large Cell Lymphoma
- Stage III Chronic Lymphocytic Leukemia
- Stage III Grade 1 Follicular Lymphoma
- Stage III Grade 2 Follicular Lymphoma
- Stage III Grade 3 Follicular Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Grade 1 Follicular Lymphoma
- Stage IV Grade 2 Follicular Lymphoma
- Stage IV Grade 3 Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CART-19

## Key facts

- **NCT ID:** NCT01029366
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-17
- **Primary completion:** 2015-07
- **Final completion:** 2016-05
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029366, "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01029366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*